Cencora, Inc. (NYSE:COR) Shares Sold by Prudential PLC

Prudential PLC lowered its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 15.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,546 shares of the company's stock after selling 5,999 shares during the quarter. Prudential PLC's holdings in Cencora were worth $7,537,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of COR. JFS Wealth Advisors LLC grew its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora during the fourth quarter worth about $30,000. Kentucky Trust Co purchased a new stake in Cencora in the fourth quarter valued at approximately $33,000. Householder Group Estate & Retirement Specialist LLC increased its holdings in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares during the period. Finally, WASHINGTON TRUST Co raised its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after buying an additional 46 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

COR traded up $4.19 during trading on Thursday, hitting $278.08. The company's stock had a trading volume of 775,417 shares, compared to its average volume of 1,495,171. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $53.92 billion, a price-to-earnings ratio of 39.62, a P/E/G ratio of 1.31 and a beta of 0.55. The business's fifty day simple moving average is $259.12 and its 200 day simple moving average is $244.21. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Analyst Ratings Changes

COR has been the topic of several recent research reports. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $280.20.

Insider Activity

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 over the last three months. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.